PWSA Blog

FDA Accepts Application for New Drug DCCR, Moves to Priority Review

Exciting news for the Prader-Willi syndrome (PWS) community!

Soleno Therapeutics has announced that the FDA has accepted their new drug application (NDA) for DCCR, a drug designed to treat hyperphagia in individuals with PWS aged 4 and older. This acceptance is a major first step, and the FDA has granted Priority Review, recognizing the potential of DCCR to significantly improve the lives of those affected by PWS. A final decision is expected by December 27, 2024.

While this is just the first step in the FDA’s decision-making process, it’s a promising development toward making DCCR available for our loved ones. Soleno Therapeutics CEO, Dr. Anish Bhatnagar, expressed gratitude to the entire PWS community, including patients, caregivers, and advocacy groups, for their continued support. 

Thank you to everyone in the PWS community for your ongoing support! Read Soleno’s full press release announcement by clicking the button below.

Share this!

Scroll to top